NEW YORK (GenomeWeb News) – Rheonix has raised $14 million through a private placement of debt and equity, the Ithaca, NY-based molecular diagnostics company said today.

Rheonix intends to use the funds to remodel its existing space and add a new headquarters to its physical operations. The firm said the remodeling and expansion will enable it to scale up manufacturing capabilities and capacity as it begins production of the Rheonix Chemistry and Reagent Device, or CARD, cartridges for its molecular diagnostic system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.

In Science this week: self-assembly of DNA components in solution, and more.